Skip to content

Additive hepatoprotective effects of semaglutide and resmetirom combination therapy in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH

  • Henrik

Background & Aim: Resmetirom (THR-β receptor agonist) has recently been approved for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and semaglutide (GLP-1R agonist) is in late-stage clinical development for treatment of MASH. The present study aimed to characterize metabolic, biochemical,…

Read more
Back To Top